Hypothyroidism Drug May Cause Psychiatric Morbidity
A study conducted in Sweden found that the combination of liothyronine (LT3) and levothyroxine (LT4) therapy in patients with autoimmune hypothyroidism is linked to a higher risk of psychiatric morbidity. Specifically, patients on this combination therapy had a 43% increased risk of developing any psychiatric issues compared to those on LT4 alone. The findings suggest that the use of LT3 may be associated with underlying vulnerabilities in mental health rather than being the direct cause of psychiatric conditions.
- ▪The study included 184,266 patients with autoimmune hypothyroidism who initiated thyroid hormone replacement therapy.
- ▪Patients exposed to LT3 plus LT4 had a 43% higher risk for any psychiatric morbidity than those on LT4 only.
- ▪Women and patients younger than 30 years had a higher risk for psychotic morbidity when exposed to LT3 plus LT4.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with autoimmune hypothyroidism, the initiation of liothyronine (LT3) in combination with levothyroxine (LT4) therapy was associated with an increased risk of developing any psychiatric morbidity, particularly affective or anxiety morbidity.METHODOLOGY:Researchers in Sweden conducted a retrospective population-based cohort study to evaluate the association between exposure to LT3 plus LT4 therapy and the risk of developing psychiatric morbidity in adults with autoimmune hypothyroidism.They included 184,266 patients with autoimmune hypothyroidism (median age, 47 years; 77.8% women) who newly initiated thyroid hormone replacement therapy and did not have prior psychiatric morbidity.Of these patients, 5346 were exposed to LT3 plus LT4 (median age, 41 years; 88.5% women)…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
